Lucca, Italy

Andrea Morelli



 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Andrea Morelli: Innovator in Gamma Globulin Purification

Introduction

Andrea Morelli is a notable inventor based in Lucca, Italy. He has made significant contributions to the field of biopharmaceuticals, particularly in the purification of gamma globulins from human plasma. His innovative approach has the potential to enhance industrial applications in this vital area of healthcare.

Latest Patents

Andrea Morelli holds a patent for a process titled "Process for the industrial-scale purification of gamma globulins from human plasma for industrial applications." This invention describes a novel, industrial-scale method for purifying gamma-immunoglobulins (IgG) from plasma or its fractions. The process involves two chromatographic steps: a cation exchange capture chromatography followed by a polishing anion exchange chromatography. This ensures a highly purified end product that contains no aggregates and achieves high yields. Additionally, the process includes a virus inactivation step using a solvent/detergent treatment to inactivate lipid-enveloped viruses, along with a virus removal step through nanofiltering to eliminate non-enveloped viruses.

Career Highlights

Andrea Morelli is associated with Kedrion S.p.A., a company that specializes in the production of plasma-derived therapies. His work at Kedrion has allowed him to apply his innovative techniques in a practical setting, contributing to advancements in the purification processes used in the industry.

Collaborations

Andrea has collaborated with notable colleagues, including Claudia Nardini and Claudio Farina. Their teamwork has fostered an environment of innovation and excellence in their respective fields.

Conclusion

Andrea Morelli's contributions to the purification of gamma globulins represent a significant advancement in biopharmaceutical processes. His innovative methods not only enhance product purity but also ensure safety in the use of human plasma-derived therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…